These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

569 related articles for article (PubMed ID: 30265523)

  • 1. Passive Immunotherapies for Central Nervous System Disorders: Current Delivery Challenges and New Approaches.
    Kumar NN; Pizzo ME; Nehra G; Wilken-Resman B; Boroumand S; Thorne RG
    Bioconjug Chem; 2018 Dec; 29(12):3937-3966. PubMed ID: 30265523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of Nanomedicine-Based Therapeutics in the Treatment of CNS Disorders.
    Guo ZH; Khattak S; Rauf MA; Ansari MA; Alomary MN; Razak S; Yang CY; Wu DD; Ji XY
    Molecules; 2023 Jan; 28(3):. PubMed ID: 36770950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intranasal delivery of biologics to the central nervous system.
    Lochhead JJ; Thorne RG
    Adv Drug Deliv Rev; 2012 May; 64(7):614-28. PubMed ID: 22119441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging Technologies for Delivery of Biotherapeutics and Gene Therapy Across the Blood-Brain Barrier.
    Stanimirovic DB; Sandhu JK; Costain WJ
    BioDrugs; 2018 Dec; 32(6):547-559. PubMed ID: 30306341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intranasal treatment of central nervous system dysfunction in humans.
    Chapman CD; Frey WH; Craft S; Danielyan L; Hallschmid M; Schiöth HB; Benedict C
    Pharm Res; 2013 Oct; 30(10):2475-84. PubMed ID: 23135822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in nanomedicines for diagnosis of central nervous system disorders.
    Zhang X; Zhou J; Gu Z; Zhang H; Gong Q; Luo K
    Biomaterials; 2021 Feb; 269():120492. PubMed ID: 33153757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CNS drug delivery systems: novel approaches.
    Pathan SA; Iqbal Z; Zaidi SM; Talegaonkar S; Vohra D; Jain GK; Azeem A; Jain N; Lalani JR; Khar RK; Ahmad FJ
    Recent Pat Drug Deliv Formul; 2009 Jan; 3(1):71-89. PubMed ID: 19149731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Applications of nanotechnology in drug delivery to the central nervous system.
    Saeedi M; Eslamifar M; Khezri K; Dizaj SM
    Biomed Pharmacother; 2019 Mar; 111():666-675. PubMed ID: 30611991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanomedicine-based immunotherapy for central nervous system disorders.
    Hanif S; Muhammad P; Chesworth R; Rehman FU; Qian RJ; Zheng M; Shi BY
    Acta Pharmacol Sin; 2020 Jul; 41(7):936-953. PubMed ID: 32467570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug Delivery to CNS: Challenges and Opportunities with Emphasis on Biomaterials Based Drug Delivery Strategies.
    Khambhla E; Shah V; Baviskar K
    Curr Pharm Des; 2016; 22(19):2913-22. PubMed ID: 27033697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current advances in delivery of biotherapeutics across the blood-brain barrier.
    Rajadhyaksha M; Boyden T; Liras J; El-Kattan A; Brodfuehrer J
    Curr Drug Discov Technol; 2011 Jun; 8(2):87-101. PubMed ID: 21513485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delivery of therapeutic agents to the central nervous system: the problems and the possibilities.
    Begley DJ
    Pharmacol Ther; 2004 Oct; 104(1):29-45. PubMed ID: 15500907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Challenges and opportunities in CNS delivery of therapeutics for neurodegenerative diseases.
    Barchet TM; Amiji MM
    Expert Opin Drug Deliv; 2009 Mar; 6(3):211-25. PubMed ID: 19290842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. From blood-brain barrier to blood-brain interface: new opportunities for CNS drug delivery.
    Banks WA
    Nat Rev Drug Discov; 2016 Apr; 15(4):275-92. PubMed ID: 26794270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delivering the Promise of Gene Therapy with Nanomedicines in Treating Central Nervous System Diseases.
    Luo M; Lee LKC; Peng B; Choi CHJ; Tong WY; Voelcker NH
    Adv Sci (Weinh); 2022 Sep; 9(26):e2201740. PubMed ID: 35851766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody therapies in CNS diseases.
    Freskgård PO; Urich E
    Neuropharmacology; 2017 Jul; 120():38-55. PubMed ID: 26972827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Injectable thermoresponsive hydrogels as drug delivery system for the treatment of central nervous system disorders: A review.
    Bellotti E; Schilling AL; Little SR; Decuzzi P
    J Control Release; 2021 Jan; 329():16-35. PubMed ID: 33259851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanotechnological advances for the delivery of CNS therapeutics.
    Wong HL; Wu XY; Bendayan R
    Adv Drug Deliv Rev; 2012 May; 64(7):686-700. PubMed ID: 22100125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipid nanoparticles for intranasal administration: application to nose-to-brain delivery.
    Battaglia L; Panciani PP; Muntoni E; Capucchio MT; Biasibetti E; De Bonis P; Mioletti S; Fontanella M; Swaminathan S
    Expert Opin Drug Deliv; 2018 Apr; 15(4):369-378. PubMed ID: 29338427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intranasal drug delivery to the central nervous system: present status and future outlook.
    Tayebati SK; Nwankwo IE; Amenta F
    Curr Pharm Des; 2013; 19(3):510-26. PubMed ID: 23116337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.